Questions about cold sensitivity helped doctors suspect cold agglutinin disease (CAD) as a possible cause of severe anemia, fatigue, and shortness of breath in a 93-year-old woman with heart disease, a case report suggests. “Probable CAD was initially obscured by [heart disease, blood thinner use, and possible bleeding] and…
News
Enjaymo (sutimlimab) rapidly stopped hemolysis — destruction of red blood cells — while anti-cancer treatment targeted the underlying blood cancer believed to be driving secondary cold agglutinin disease (CAD) in a 61-year-old woman. This case “adds to the growing evidence that using short-term [Enjaymo] for [secondary CAD] as…
A 55-year-old man with severe lung disease and cold agglutinin disease (CAD) successfully underwent a lung transplant with no CAD-related complications thanks to several preventive strategies, a case study reported. To avoid complications from a drop in body temperature during surgery, which could trigger CAD-related red blood cell destruction,…
Combining a complement inhibitor with rituximab was found to rapidly control severe autoimmune hemolytic anemia (AIHA), including in two patients with cold agglutinin syndrome, a condition related to cold agglutinin disease. In two of the three patients in the series, the complement inhibitor Enjaymo (sutimlimab) was later…
Careful planning, warming measures, and close teamwork between medical specialists may allow for the safe collection and transplant of blood-forming stem cells in people with cold agglutinin disease (CAD) to rebuild a healthy bone marrow after high-dose chemotherapy. That’s according to a study reporting a successful procedure in a…
Certain types of blood cancer may increase the risk of cold agglutinin disease (CAD), and while the presence of both conditions has historically been associated with worse survival, a study suggests that modern, targeted cancer treatments have reduced this negative effect. Because newer therapies are generally more effective at…
Some people with a diagnosis of cold agglutinin disease (CAD) secondary to another condition — when it’s then known as cold agglutinin syndrome, or CAS — may actually just have CAD. That’s the hypothesis set forth in a small study, involving eight people with “clinically well-characterised CAD or CAS,”…
A stem cell transplant led to lasting remission of cold agglutinin disease (CAD) secondary to an aggressive lymphoma in a 48-year-old woman, according to a case report from Japan. This was only the second reported CAD case in which levels of disease-causing self-reactive antibodies completely normalized after a stem…
A 58-year-old woman who developed cold agglutinin disease (CAD) as a complication of blood cancer improved after treatment with medications to reduce the immune attack on red blood cells, along with chemotherapy for the underlying cancer. Meanwhile, corticosteroids and other medications helped two patients with different forms of autoimmune…
Gilead Sciences and Lakefront Biotherapeutics have acquired Ouro Medicines and its investigational therapy, gamgertamig, for cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA). Gamgertamig is also being developed as a treatment for several other autoimmune diseases. Under the deal, valued at up to $2.175 billion,…
Recent Posts
- Questions about cold sensitivity helped doctors suspect CAD in older woman
- Valuing others makes me feel visible and lifts me out of my CAD depression
- Short-term treatment may rapidly control hemolysis in secondary CAD
- Church service helps guide this CAD patient from sluggishness to strength
- For whom the bell at the treatment center rings, it rings not for me